Home
Dashboard
Curated content
Themes
Innovations
Key Innovators
Key Innovators - Universities
European Innovation Council
Funding rounds
Companies
Corporates
Investors
Jobs
Support Organisations
Events
Investment heatmap
Matching tool
Companies
Arxx Therapeutics
Save
Arxx Therapeutics
Develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis.
Launch date
2019
Employees
2-10 people
Company register number
815295242
Oslo Norway (HQ)
View more
https://arxxtx.com/
https://www.linkedin.com/company/arxx-therapeutics/
B2B
manufacturing
commission
health
biotechnology
hard tech
biotechnology
Overview
Similar companies
Investments (1)
Analytics
Notes
Job openings
Innovations (0)
Patents (2)
Arxx Therapeutics funding
Arxx Therapeutics investors
Edit
Date
Investors
Amount
Round
-
ShareLab
p53 Invest
Sarsia
N/A
-
Nov 2020
Innovation Norway
NOK3.2m
Grant
Jan 2024
*
Oxitope Pharma
N/A
Merger
Total Funding
€352k
Related Content
Recent News about Arxx Therapeutics
Edit
Investments by Arxx Therapeutics
Edit
Oxitope Pharma